Scripsamerica Inc · OTC:SCRCQ
Scripsamerica — Investor Presentation (March 2015)
24 slides from Scripsamerica's investor presentation, March 2015
Slide 1: Winter 2015
Winter 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not s
Slide 3: ScripsAmerica, Inc.
ScripsAmerica, Inc. A leading, vertically integrated provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies Serving large and growing markets: Specialty Pharmaceuticals & Medical Supplies Rapid Growth, Improving Financial Performance, Projecting Q
Slide 4: Trading Snapshot
Trading Snapshot Symbol SCRC Exchange OTCBB Price (3/16/15) $0.12 Market Capitalization (3/16/15) ~ $17 MM 52- Week Range $0.08 - $0.22 Average Daily Volume 500,000 Shares Outstanding/Authorized 138MM/250MM Corporate Headquarters Tysons Corner, Virginia
Slide 5: ScripsAmerica: Evolution of A Healthcare Leader
ScripsAmerica: Evolution of A Healthcare Leader 2008 Founded 2010 Operations Commence 2010 – 2012 Pharmaceutical distribution services (primarily McKesson) Retail, hospitals, long-term care facilities and government and home care agencies 2013 McKesson squeezes margins, increases chargebac
Slide 6: One Platform – Multiple Opportunities
One Platform – Multiple Opportunities ScripsAmerica Established Operations Evolving Operations Main Avenue PIMD Wholesale Rx Evolving Businesses Pharmacy February ‘15 E2014 Revenues Revenues @$29,000,000.00 @$554,000.00 Physician Diabetic RapiMed Dispensing Supplies $200,000 Order 700+ Pending Patie
Slide 7: The Specialty Pharmaceuticals Market
The Specialty Pharmaceuticals Market Estimated 1% - 5% of population cannot tolerate medications in standard formulas* Specialty pharmacy industry growth drivers: Shortages of mass-produced drugs Growth in the senior citizen population Increased awareness of compounding pharmacies and pharmaceu
Slide 8: ScripsAmerica’s Specialty Pharma Business
ScripsAmerica’s Specialty Pharma Business Main Avenue Pharmacy acquired Feb. 14, 2014 (100% effective October 2014) Offering a wide variety of specialty pharmaceutical products to treat pain, scars, wounds, vitamin deficiencies among others FDA approved and licensed in 10 states Additional s
Slide 9: Pre-Approval Avoids Collection Risk
Pre-Approval Avoids Collection Risk Doctor writes prescription Submitted for payment to Insurance Company/Third party payers No Medicaid, Medicare 200 6 Prescription approved for payment Order to compound transmitted to Main Avenue Pharmacy Bill generated & sent to Insurer/3rd Party Payer
Slide 10: Case Study: Just One of ScripsAmerica’s Many Products
Case Study: Just One of ScripsAmerica’s Many Products More than 100 million Americans suffer from chronic pain 83% reported significant reduction in their pain after using custom-compounded prescription pain creams On average, survey respondents said the creams reduced their pain levels by more
Slide 11: Specialty Pharmaceuticals Growth Strategy
Specialty Pharmaceuticals Growth Strategy Expand Licensing to New States Add Pharmacies Two Pharmacies under LOI - will add 30 states Bring on Additional Marketing Partners Introduce New Products
Slide 12: Other Growth Platforms
Other Growth Platforms RapiMed – Child Pain & Fever Relief tablets- Approval Pending PIMD International Physician Dispensing Program Diabetic Medical Supplies
Slide 13: RapiMed Oral Delivery Technology
RapiMed Oral Delivery Technology Rapid Release, Fast Dissolving Fever & Pain Relief Tablets Over The Counter Product Manufactured in United States Regulated dosage (80mg, 160mg) for children 2 – 11 Signed Contract with Distributor in China $200,000 order pending- $60,000 Cost (Attractive M
Slide 14: PIMD International, LLC
PIMD International, LLC Problem: Small chains/individual pharmacies unable to fill prescriptions for controlled substances Product manufacturers impose minimum order quantities far beyond the needs of the smaller operations Solution: A DEA and State licensed business that represents independen
Slide 15: Physician Dispensing Program
Physician Dispensing Program Nearly all States have regulations governing the dispensing of drugs by physicians Typical Regulations: Dispensing in limited situations State agencies licensure Limit profits on drugs dispensed by physicians Protect freedom of choice for consumers Procedural con
Slide 16: Strong, Experienced Leadership Team
Strong, Experienced Leadership Team Robert Schneiderman, CEO & Founder Accomplished entrepreneur with proven track record building businesses and creating value for shareholders CEO of one of Philadelphia’s leading recruitment firms for 32 years Jeffrey Andrews, CFO Finance professional with e
Slide 17: Financial Results
Financial Results >
Slide 18: Recent Results of Operations
Recent Results of Operations Significant Improvement In millions, except EPS 2014 (P) 2013 Improvement Net Revenues $ 31.5 $ 0.60 + $ 29.9 Operating Income ($ 0.01) ($ 7.4) + $ 7.4 Net (Loss) ($ 1.2) $(11.3) + $ 10.1 EPS ($ 0.01) ($ 0.17) + $ 0.16 Shares 127.5 68.1 (P) Preliminary results, subject t
Slide 19: First Quarter 2015 Profitable
First Quarter 2015 Profitable March 31, March 31, 2015 2014 (Projected) (Actual) (3 months) (3 months) Revenue $ 9,600,000 $ 800,000 Operating Income* $ 1,001,000 $ 612 Income (loss) from Operations $ 594,000 ($ 214,000) Net Income (loss)** $ 407,000 ($1,213,000) * prior to shares issued for service
Slide 20: Strong & Improving Financial Position
Strong & Improving Financial Position December 31, 2014* December 31, 2013 * (000’s omitted) Cash $ 730 $ 47 Receivables $ 2,679 $ 1,089 Inventory $ 1,011 $ -0- Total Current Assets $ 4,699 $ 1,490 Total Assets $ 5,659 $ 1,781 Line of Credit $ 653 $ 99 Payables & Accruals $ 2,268 $ 227 Purchase Orde
Slide 21: Capital Structure
Capital Structure 12/31/14 12/31/13 Working Capital $1.350 MM ($1.698 MM) 149 Shareholders of record ~ 50% owned by 10 "Friends & Family" Shareholders Preferred Convertible Debt - $1MM-Held by Board Member, Convertible into 6MM shares Term Debt – $233,000, 9% due 9/2016. Holder: Board memb
Slide 22: ScripsAmerica — Summary
ScripsAmerica — Summary >
Slide 23: ScripsAmerica – Strategy
ScripsAmerica – Strategy Expand the Compounding Rx Business -Add new Pharmacies, Products and Formulations Launch RapiMeds Launch Physician Dispensing Program Add New Formulations of the Oral Delivery Technology Strategic Acquisitions Eliminate Convertible Notes/Pay Off Unsecured Debt
Slide 24: Contact Information
CONTACT INFORMATION www.scripsamerica.com Robert Schneiderman, CEO 800-957-7622 ext 101 bob@scripsamerica.com Jeffrey J. Andrews, CFO 800-957-7622 ext 102 Jeff@scripsamerica.com